Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Competitors to Theravance Biopharma, Inc. - Ordinary Shares (TBPH)
Acorda Therapeutics
Acorda Therapeutics primarily focuses on therapies for neurological disorders and has strengths in improving mobility, which offers them a favorable point of competition against Theravance in specific indications. While Acorda is smaller than Theravance, their specialized approach and niche focus allow them to compete effectively within that sector. However, Theravance's broader pipeline and partnerships in various therapeutic areas provide them with a stronger market positioning overall.
Amgen, Inc. AMGN -0.94%
Amgen is a biopharmaceutical giant that has a diverse portfolio of products across various therapeutic areas, including oncology and inflammation, which often overlaps with some of Theravance's targets. Amgen competes by leveraging its extensive resources, experience in late-stage development, and robust commercialization capabilities. This allows Amgen to quickly adapt to market needs and invest in breakthrough therapies, positioning it ahead of Theravance in many therapeutic areas.
Boehringer Ingelheim
Boehringer Ingelheim competes with Theravance Biopharma through its broad pharmaceutical portfolio and a strong focus on respiratory diseases, where both companies are active. The comprehensive research capabilities and financial strength of Boehringer Ingelheim provide them with a significant advantage in bringing new drugs to market and conducting extensive clinical trials. Additionally, their established presence in various markets allows them to leverage existing relationships and regulatory experience, giving them an upper hand against Theravance.
Spectrum Pharmaceuticals
Spectrum Pharmaceuticals competes with Theravance Biopharma mainly in the oncology space, where they both focus on developing innovative therapies for cancer. Spectrum's competitive strategy includes seeking niche markets and rare cancers, which allows them to establish themselves within specific segments of the oncology market. While they have a number of therapeutic products in the pipeline, Theravance's more diversified approach and integral partnerships may give it an edge over Spectrum in terms of innovation and market reach.
Vertex Pharmaceuticals VRTX -3.20%
Vertex Pharmaceuticals competes with Theravance Biopharma through its focus on innovative treatments for serious diseases, particularly in cystic fibrosis and pain management. Both companies prioritize the development of new therapies, but Vertex has established a strong market presence with its successful CFTR modulators, giving it an edge in the biotech marketplace compared to Theravance's offerings. Moreover, Vertex's robust pipeline and strategic partnerships allow it to maintain a competitive advantage in research and development.